華仁藥業(300110.SZ):擬吸收合併華仁堂健康科技
格隆匯12月29日丨華仁藥業(300110.SZ)公佈,公司於2022年12月29日召開第七屆董事會第十九次(臨時)會議,審議通過了《關於吸收合併全資子公司及變更經營範圍暨修訂<公司章程>的議案》,為優化資源配置、降低管理成本、提高運營效率,結合公司戰略發展規劃,公司擬吸收合併全資子公司青島華仁堂健康科技有限公司(“華仁堂健康科技”)。同時,鑑於被合併全資子公司相關業務合併至公司,結合公司經營業務及戰略發展佈局,公司擬變更經營範圍並對《公司章程》相應條款進行修訂。該議案尚需提交公司股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.